Rodriguez-Morales Alfonso J, Martinez-Pulgarin Dayron F, Muñoz-Urbano Marcela, Gómez-Suta Daniela, Sánchez-Duque Jorge A, Machado-Alba Jorge E
Public Health and Infection Research Group, Faculty of Health Sciences, Universidad Tecnológica De Pereira, Pereira, Risaralda, Colombia.
Ophthalmology, Universidad Nacional de Colombia.
Cureus. 2017 May 1;9(5):e1204. doi: 10.7759/cureus.1204.
Nitazoxanide is a member of a new class of drug, thiazolides, and it was discovered in 1984 with antimicrobial activity effect against anaerobic bacteria, Hepatitis virus, protozoa, and helminths.
A bibliometric study on four databases (1984-2016) - Medline, Scopus, LILACS, and SciELO - characterizing the global scientific production of nitazoxanide. We determined the quantity, quality (number of citations), and types of studies developed by each country, characterizing them by years, international cooperation, development, place of publication, authors (with its H-index), and groups with higher impact.
There were 512 articles in Medline - the higher scientific production is from the USA (19.71%), Switzerland (7.51%), and Mexico (7.27%). There were 1,440 articles in Scopus - from the USA (8.98%), Mexico (2.13%), and India (1.65%). There were 405 articles in LILACS - from Mexico (4.69%), the USA (4.2%), and Peru (2.47%). There were 47 articles in SciELO - from Brazil (34.04%), Venezuela (21.28%), and Colombia (14.89%). The H-index of nitazoxanide is 75 - the USA (26), Egypt (12), and Canada (10) were the countries contributing more with that.
Nitazoxanide research has been highly important. Nevertheless, it is relatively limited when compared with other drugs. Its research has been led by the USA, as revealed in this bibliometric assessment. Although some developing countries, where it is used especially for protozoa and helminths, probably have its influence, and this explains the fact that Mexico and India, among others, are the top countries in the scientific production of this anti-infective agent. This bibliometric study evidenced a relatively low number of publications, however, it has been increased in recent years.
硝唑尼特是一类新型药物噻唑啉类的成员,于1984年被发现,具有抗厌氧菌、肝炎病毒、原生动物和蠕虫的抗菌活性。
对四个数据库(1984 - 2016年)——医学索引数据库(Medline)、斯高帕斯数据库(Scopus)、拉丁美洲及加勒比地区卫生科学数据库(LILACS)和科学电子图书馆在线数据库(SciELO)进行文献计量学研究,以描述硝唑尼特的全球科研产出情况。我们确定了每个国家开展的研究数量、质量(被引次数)和研究类型,并按年份、国际合作、发展情况、发表地点、作者(及其H指数)以及影响力较大的研究团队进行了特征描述。
医学索引数据库中有512篇文章——科研产出最多的是美国(19.71%)、瑞士(7.51%)和墨西哥(7.27%)。斯高帕斯数据库中有1440篇文章——来自美国(8.98%)、墨西哥(2.13%)和印度(1.65%)。拉丁美洲及加勒比地区卫生科学数据库中有405篇文章——来自墨西哥(4.69%)、美国(4.2%)和秘鲁(2.47%)。科学电子图书馆在线数据库中有47篇文章——来自巴西(34.04%)、委内瑞拉(21.28%)和哥伦比亚(14.89%)。硝唑尼特的H指数为75——美国(26)、埃及(12)和加拿大(10)在这方面贡献较大。
硝唑尼特研究一直非常重要。然而,与其他药物相比,其研究相对有限。正如这项文献计量学评估所揭示的,其研究一直由美国主导。尽管一些特别将其用于治疗原生动物和蠕虫感染的发展中国家可能受到了影响,这也解释了墨西哥和印度等国是这种抗感染药物科研产出最多的国家之一这一事实。这项文献计量学研究表明该药物的出版物数量相对较少,不过近年来有所增加。